Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression data from anti-mycoplasma drugs treated gastric cancer cells

ABSTRACT: Various anti-mycoplasma drugs have different effects on cells growth We used microarrays to detail the global programme of gene expression underlying gastric cancer cells treated with anti-mycoplasma drugs and identified distinct classes of up-regulated genes during this process.

ORGANISM(S): Homo sapiens

PROVIDER: GSE73777 | GEO | 2015/10/08

SECONDARY ACCESSION(S): PRJNA298030

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Sirtuin 3 is a common target of non-steroidal anti-inflammatory drugs to induce gastric cancer cell death and gastric mucosal injury.

Project description:Nonsteroidal anti-inflammatory drugs (NSAIDs), the quintessential medicines to treat pain and inflammatory conditions, induce cell death in human cancer cells, as repurposed anticancer agents, and in normal gastric mucosa, as a major side effect. The subcellular target/s of NSAIDs that leads to the cell death remained elusive so far. Here, by venturing transcriptomics followed by functional validation, we, for the first time, identified mitochondrial deacetylase Sirtuin 3 (Sirt3) as a non-canonical target of NSAIDs whose depletion induced the hyperacetylation of mitochondrial proteome, OGG1 depletion, mtDNA damage, electron transport chain defect associated mitochondrial dysfunction and finally cell death. Silencing of Sirt3 in AGS cells (a human gastric adenocarcinoma cell line) significantly aggravated NSAID-induced cytopathology. Whereas, honokiol mediated induction of Sirt3 corrected the NSAID-induced transcriptome alteration and gastropathy in rodent model. Together, the results identify Sirt3 as a common target used by NSAIDs to induce gastric carcinoma cell death and gastric mucosal injury.

2022-11-14 | GSE201565 | GEO

Sirtuin 3 is a common target of non-steroidal anti-inflammatory drugs to induce gastric cancer cell death and gastric mucosal injury II.

2022-11-14 | GSE202140 | GEO

Phenome analysis of Mycoplasma pneumoniae

Project description:To discover new gene functions in Mycoplasma pneumoniae, cells were treated with different drugs/perturbations.

2016-04-01 | E-MTAB-3771 | biostudies-arrayexpress

Homo sapiens

Project description:Expression data from anti-mycoplasma drugs treated gastric cancer cells

| PRJNA298030 | ENA

Transcriptome analysis of Mycoplasma pneumoniae I

Project description:To reconstruct the gene regulatory network of Mycoplasma pneumoniae, cells were treated with different drugs/perturbations or were challenged by gain or loss of function of candidate regulators, or a combination of both.

2016-04-01 | E-MTAB-3772 | biostudies-arrayexpress

Transcriptome analysis of Mycoplasma pneumoniae II

2016-04-01 | E-MTAB-3773 | biostudies-arrayexpress

Transcriptome analysis of Mycoplasma pneumoniae III

2019-07-31 | E-MTAB-4642 | biostudies-arrayexpress

Transcriptome analysis of Mycoplasma pneumoniae V

2019-07-31 | E-MTAB-6229 | biostudies-arrayexpress

Expression data in sera from patients with anti-tuberculosis drug-induced liver injury

Project description:The pathogenesis of liver damage induced by anti-tuberculosis drugs is not fully understood, andcurrently, there is no clinically useful biomarker for early diagnosis and treatment.By comparing the differences in the expression of global gene transcripts in the serum of patients with and without anti-tuberculosis drugs induced liver injury, dysregulation genes not only provides a basis for studying pathogenesis, but also provides important information to find new targets for diagnosis and treatment of disease. We used microarrays to detail the global programme of gene expression in sera underlying anti-tuberculosis drug-induced liver injury and identified distinct classes of transcript during this process.

2021-01-01 | GSE141362 | GEO

Anti-cancer drugs curaxins target the 3D genome organization

Project description:Anti-cancer drugs curaxins target the 3D genome organization

| PRJNA505307 | ENA